Conclusion:Serum metabolomics is a feasible app roach to identifying novel biomarkers of SA-AKI.Phosphoethanolamine metabolites both distinguished AKI from sepsis controls and were correlated with clinical severity (estimated glomerular filtration rate decline), suggesting its potential prognostic value.However, its diagnostic feasibility requires preliminary validation in larger multicenter cohorts.
Chaudhary et al. (Wed,) studied this question.